Phase II study of imatinib in advanced chordoma.
暂无分享,去创建一个
R. Stupp | P. Casali | C. Spreafico | S. Pilotti | A. Bertuzzi | A. Gronchi | S. Stacchiotti | A. Messina | V. Ferraresi | G. Grignani | A. Longhi | E. Tamborini | A. Comandone | V. Vinaccia | P. Amore
[1] P. Casali,et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Shalaby,et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target , 2011, The Journal of pathology.
[3] P. Casali,et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. , 2010, Neuro-oncology.
[4] Alessandra Bolsi,et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. , 2009, International journal of radiation oncology, biology, physics.
[5] P. Casali,et al. Response to imatinib plus sirolimus in advanced chordoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Parnis,et al. Response to erlotinib in a patient with treatment refractory chordoma. , 2009, Anti-cancer drugs.
[7] A. D. Van den Abbeele,et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Yeap,et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. , 2009, International journal of radiation oncology, biology, physics.
[9] G. Nielsen,et al. Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas , 2009, Clinical Cancer Research.
[10] R. Pallini,et al. Clivus metastases: Report of seven patients and literature review , 2009, Acta Neurochirurgica.
[11] P. Casali,et al. Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.
[12] L. Stenberg,et al. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib , 2009, Acta oncologica.
[13] L. Mariani,et al. Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers , 2009, Annals of Surgical Oncology.
[14] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Laing,et al. High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1--Clinical outcomes. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).
[16] A. Samii,et al. Chordomas of the skull base: surgical management and outcome. , 2007, Journal of neurosurgery.
[17] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[18] U. Pastorino,et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas , 2007, The Journal of pathology.
[19] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Debus,et al. Effectiveness of Cetuximab/Gefitinib in the Therapy of a Sacral Chordoma , 2006, Oncology Research and Treatment.
[21] P. Casali,et al. Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas , 2006, Clinical Cancer Research.
[22] Z. Gokaslan,et al. Metastatic disease from spinal chordoma: a 10-year experience. , 2006, Journal of neurosurgery. Spine.
[23] L. Sekhar,et al. Patient Outcome at Long-term Follow-up after Aggressive Microsurgical Resection of Cranial Base Chordomas , 2006, Neurosurgery.
[24] P. Casali,et al. PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma , 2006 .
[25] J. Weinstein,et al. Chordoma of the Mobile Spine: Fifty Years of Experience , 2006, Spine.
[26] C. Matula,et al. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression , 2005, Anti-cancer drugs.
[27] P. Casali,et al. Imatinib mesylate in 18 advanced chordoma patients , 2005 .
[28] V. Sondak,et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] F. Grosso,et al. Imatinib mesylate in chordoma , 2004, Cancer.
[30] E. Jannini,et al. Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-α and -β during Human Testicular Development and Disease , 2002 .
[31] C. Haie-meder,et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience. , 2001, International journal of radiation oncology, biology, physics.
[32] Janice,et al. A multidisciplinary team approach to skull base chordomas. , 2001, Journal of neurosurgery.
[33] L. Kindblom,et al. Prognostic factors in chordoma of the sacrum and mobile spine , 2000, Cancer.
[34] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[35] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[36] A. Rosenberg,et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. , 1999, Journal of neurosurgery.
[37] G. Fuller,et al. Sacral chordoma: 40-year experience at a major cancer center. , 1999, Neurosurgery.
[38] P. Scimeca,et al. Chemotherapeutic Treatment of Malignant Chordoma in Children , 1996, Journal of pediatric hematology/oncology.
[39] J. Wunder,et al. Chordoma: long-term follow-up after radical photon irradiation. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[40] G. Demetri,et al. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. , 1995, Hematology/oncology clinics of North America.
[41] C. Cleeland,et al. Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.
[42] E. Laws,et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients , 1993, Cancer.
[43] C. P. Schwinn,et al. Chordoma. A clinicopathologic study of metastasis. , 1979, American journal of clinical pathology.
[44] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[45] D. Razis,et al. Chordoma of the cervical spine treated with vincristine sulfate. , 1974, Journal of medicine.
[46] H. O. Hustu,et al. Chordoma. Thirty‐five‐year study at memorial hospital , 1967, Cancer.
[47] A. McSweeney,et al. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordoma therapy. , 1959, A.M.A. archives of surgery.
[48] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .